explore -WSS

explore

author：comprehensive 2025-10-04 11:35:53 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： AstraZeneca bets AAV gene therapy will still deliver the goods

WSS

Apellis safety probe of eye disease drug centers on injection needle

With Roe v Wade overturned, abortion providers work to adapt

How to make Best Hospitals ratings actually useful for patients

Study points to new risk in gene therapy death of Terry Horgan

The United States is paying nearly triple for new Covid vaccines

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

hotspot

explore

hotspot

Cancer drug shortages should be causing more outrage

Complete sequence of Y chromosome published for first time

ChatGPT in medicine: STAT answers readers' burning questions

New oral drug delivery patch is modeled after octopus tentacles

Virginia high school admissions case could be legal follow

The Karikó problem: Lessons for funding basic research

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Neuroscience startup Neumora files for IPO

Hepatitis C has a cure — but many Americans still lack access to it

Congress extends some pandemic preparedness programs

entertainment

New oral drug delivery patch is modeled after octopus tentacles

Some top drug companies are starting to take action on climate

Why more medical students aren't specializing in primary care

Congress extends some pandemic preparedness programs

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

How Long Island became the ‘eugenics capital of the world’

knowledge

entertainment

explore

leisure time